HOME >> MEDICINE >> NEWS
ILEX Oncology & LeukoSite report results from pivotal Phase II CAMPATH (R) trial; Results suggest new hope for refractory chronic lymphocytic leukemia

Results suggest new hope for patients with refractory chronic lymphocytic leukemia Data to support BLA submission

BARCELONA, SPAIN, June 12 ---ILEXTM Oncology, Inc. (NASDAQ: ILXO) and LeukoSite, Inc. (NASDAQ: LKST) today announced final results from an international, multi-center, pivotal Phase II clinical trial of CAMPATHR for the treatment of patients with B-cell chronic lymphocytic leukemia (CLL) who are refractory to fludarabine. Results of the trial were presented this weekend at the 4th Congress of the European Haematology Association (EHA) by Michael J. Keating, MB, BS, of the M.D. Anderson Cancer Center, one of the trial's principal investigators and an internationally recognized expert in CLL. The companies plan to submit a Biologics License Application (BLA) based largely on these results later this year.

"The results of this trial are encouraging," said Dr. Keating, Associate Head for Clinical Research and Professor of Medicine and internist for the Department of Leukemia at M.D. Anderson Cancer Center. "The data suggest that CAMPATH may provide an important new treatment option for fludarabine-refractory patients, a group for whom the prognosis has, to date, been extremely poor. While the treatment of patients with leukemia has relied on chemotherapeutic agents, the use of monoclonal antibodies is an innovative approach to circumventing the disease's mechanisms for resistance."

The non-comparative trial, involved 93 previously treated patients who had received prior alkylating agents and failed fludarabine therapy (median of three prior treatment regimens). For these patients, the median life expectancy is usually six to nine months.

In the trial, patients participating at the 20 clinical sites in the United States and Europe received 30 mg of CAMPATH on an outpatient basis, as an intravenous infusion, three times a week, for four to 12 weeks. The dose was gradually escalated over the first week to 30 mg, in or
'"/>

Contact: Deborah Sibley, ILEX Oncology
210-949-8287
Porter Novelli
12-Jun-1999


Page: 1 2 3 4 5

Related medicine news :

1. The 23rd Congress of the European Society for Therapeutic Radiology and Oncology (ESTRO)
2. Oncology Nursing Society honors Fox Chase Cancer Center nurse with Radiation Therapy Nursing Award
3. The Lancet Oncology (TLO)
4. The Lancet Oncology press release
5. The Lancet Oncology (TLO) and the Lancet Infectious Diseases (TLID)
6. The Lancet Oncology (TLO) June 2002
7. The Lancet Oncology (TLO) and The Lancet Infectious Diseases (TLID)
8. The Lancet Oncology and The Lancet Infectious Diseases
9. V. Craig Jordan Will Present Results Of Raloxifene Breast Cancer Study At American Society For Clinical Oncology Meeting
10. First UK cases of previously rare disease reported in gay men
11. Health care report cards may increase racial/ethnic disparities in bypass operations

Post Your Comments:
(Date:3/30/2015)... This report studies the global pharmacovigilance and drug ... 2014 to 2019. This market is expected to ... to 2019. , Further Inquiry @ http://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=16831714 ... and drug safety software market has been classified ... namely, adverse event reporting software, drug safety audits ...
(Date:3/30/2015)... New York, New York (PRWEB) March 30, 2015 ... of its Top 10 Exotic Water Awards, with the top ... other winners are listed on the company’s website, along with ... Water’s website, exotic water, glacial water, spring water, mineral water ... Fiji water is one of the top exotic water ...
(Date:3/30/2015)... FMC Corporation’s Health and Nutrition division ... Epax® Ultra and Core concentrates manufactured in the ... ensures the manufacturing process and all physical raw ... for Halal. , The new Halal certification ... advance its customer service to a global market ...
(Date:3/30/2015)... Slidezilla, an app from the makers of ... innovates the fun and simplicity of photo slideshows. The ... slideshows and then instantly share them across their Facebook, ... to create a slideshow app where users can share ... options to personalize them. You can choose your own ...
(Date:3/30/2015)... V/NO (Virtually No Alcohol) Wines have a sleek ... and for reuse. Consumers simply twist the cup, turn it ... professionals, and basically anyone can now enjoy a non-alcoholic ... socially or pair with meals at work, home, or wherever ... and that means Napa Wine grapes undergo the traditional ...
Breaking Medicine News(10 mins):Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 2Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 3Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 4Health News:Best Exotic Water Brands Acclaimed by 10 Best Water 2Health News:FMC Health and Nutrition Announces Halal Certification for Epax® Brand Omega-3 Ingredients 2Health News:Napa Valley Alcohol-Removed Red, White & Rosé Wines Have Launched. 2
(Date:3/30/2015)... March 30, 2015   GlassesUSA , the online retailer ... $12.5 million in new financing led by Viola Private ... will further GlassesUSA,s aggressive business growth and accelerate their expansion ... online eyewear, both B2C and B2B. GlassesUSA was ... Eldad Rothman , and CTO Roy Yamner . ...
(Date:3/30/2015)... HA,AYIN, Israel , March 30, 2015 ... of Dr. Yuval Avni as the company,s ... partner at Giza VC, a leading early stage Israeli ... with clinical experience in general and vascular surgery.   ... company also announced today that Sherpa Innoventures is Beta-O2,s ...
(Date:3/30/2015)... Pharmaceuticals Corporation (NASDAQ: RXII ), a biotechnology ... primarily in the areas of dermatology and ophthalmology ... financial results for the fourth quarter and year ... update. Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ... a steady growth and evolution for RXi Pharmaceuticals," ...
Breaking Medicine Technology:GlassesUSA.com Raises $12.5 Million Growth Round Led By Viola Private Equity 2GlassesUSA.com Raises $12.5 Million Growth Round Led By Viola Private Equity 3Beta-O2 Names Dr. Yuval Avni CEO 2Beta-O2 Names Dr. Yuval Avni CEO 3RXi Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial Results and Recent Corporate Highlights 2RXi Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial Results and Recent Corporate Highlights 3RXi Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial Results and Recent Corporate Highlights 4RXi Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial Results and Recent Corporate Highlights 5RXi Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial Results and Recent Corporate Highlights 6RXi Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial Results and Recent Corporate Highlights 7RXi Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial Results and Recent Corporate Highlights 8RXi Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial Results and Recent Corporate Highlights 9RXi Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial Results and Recent Corporate Highlights 10
Cached News: